Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
28 Février 2024 - 1:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of February 2024
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant’s name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference
into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and
333-265866.
The following exhibit is attached:
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 2024 |
KAMADA LTD. |
|
|
|
By: |
/s/ Nir Livneh |
|
|
Nir Livneh |
|
|
Vice President General Counsel and Corporate Secretary |
EXHIBIT INDEX
3
Exhibit 99.1
Kamada to Announce Fourth Quarter and Fiscal
Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
Company to Host Conference Call at 8:30am ET
Rehovot, Israel, and Hoboken, NJ, February
28, 2024 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed
products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release
financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to
the open of the U.S. financial markets on Wednesday, March 6, 2024.
Kamada
management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and
answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within
the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference
ID 13744277. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1655132&tp_key=6e560eef4a.
The call
will also be archived for 90 days on the Company’s website at www.kamada.com.
About Kamada
Kamada Ltd. (the “Company”) is a commercial
stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in
the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative
development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable
growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical
fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB®,
CYTOGAM®, VARIZIG®, WINRHO SDF®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of
equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic
partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India,
Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in
the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers
and in addition have eleven biosimilar products in its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA)
and Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma
collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of
KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new
product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which
it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI
Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning
approximately 38% of the outstanding ordinary shares.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
(212) 915-2578
britchie@LifeSciAdvisors.com
Kamada (NASDAQ:KMDA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Kamada (NASDAQ:KMDA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024